Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

819 indexed citations
published 1998

Countries where authors are citing Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Specialization
Citations

This map shows the geographic impact of Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry more than expected).

Fields of papers citing Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

About Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

This paper, published in 1998, received 819 indexed citations . Written by J Michael Kilby, Sam Hopkins, Gretchen A. Cloud, Jeannette Lee, Eric Hunter, Dennis M. Lambert, Dani P. Bolognesi, Thomas J. Matthews, George M. Shaw and Michael S. Saag covering the research area of Virology and Infectious Diseases. It is primarily cited by scholars working on Virology (621 citations), Infectious Diseases (512 citations) and Molecular Biology (221 citations). Published in Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1038/3293.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026